BR112018069105A2 - pirimidinas e variantes das mesmas, e usos para tais - Google Patents

pirimidinas e variantes das mesmas, e usos para tais

Info

Publication number
BR112018069105A2
BR112018069105A2 BR112018069105A BR112018069105A BR112018069105A2 BR 112018069105 A2 BR112018069105 A2 BR 112018069105A2 BR 112018069105 A BR112018069105 A BR 112018069105A BR 112018069105 A BR112018069105 A BR 112018069105A BR 112018069105 A2 BR112018069105 A2 BR 112018069105A2
Authority
BR
Brazil
Prior art keywords
pyrimidines
variants
present
potential treatment
provides
Prior art date
Application number
BR112018069105A
Other languages
English (en)
Other versions
BR112018069105B1 (pt
Inventor
P Ford Anthony
R Gever Joel
Ibrahim Prabha
Charles Hawley Ronald
Original Assignee
Afferent Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Afferent Pharmaceuticals Inc filed Critical Afferent Pharmaceuticals Inc
Publication of BR112018069105A2 publication Critical patent/BR112018069105A2/pt
Publication of BR112018069105B1 publication Critical patent/BR112018069105B1/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/48Two nitrogen atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/14Antitussive agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/50Three nitrogen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

Abstract

a presente invenção fornece compostos de pirimidina de fórmula 1 e usos das mesmas, por exemplo, para o tratamento potencial de doenças associadas com receptores purinérgicos p2x. em certos aspectos, a presente invenção fornece antagonistas de p2x3 e/ou p2x2/3 que são úteis, por exemplo, para o tratamento potencial de doenças, condições e transtornos de órgãos viscerais, cardiovasculares e relacionados à dor.
BR112018069105-4A 2016-03-25 2017-03-20 Composto de pirimidina, composição e uso do mesmo BR112018069105B1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662313334P 2016-03-25 2016-03-25
US62/313,334 2016-03-25
PCT/US2017/023126 WO2017165255A1 (en) 2016-03-25 2017-03-20 Pyrimidines and variants thereof, and uses therefor

Publications (2)

Publication Number Publication Date
BR112018069105A2 true BR112018069105A2 (pt) 2019-01-29
BR112018069105B1 BR112018069105B1 (pt) 2024-08-06

Family

ID=

Also Published As

Publication number Publication date
JP6902045B2 (ja) 2021-07-14
MA44489A (fr) 2019-01-30
KR20180128015A (ko) 2018-11-30
KR102377805B1 (ko) 2022-03-22
US20200239421A1 (en) 2020-07-30
CA3018180A1 (en) 2017-09-28
WO2017165255A1 (en) 2017-09-28
AU2017237929B2 (en) 2021-04-15
EP3433258B1 (en) 2023-07-19
US11230532B2 (en) 2022-01-25
RU2760733C2 (ru) 2021-11-30
EP3433258A4 (en) 2019-10-30
CN108779119B (zh) 2022-02-08
MX2018011622A (es) 2019-03-28
US20190055202A1 (en) 2019-02-21
CN108779119A (zh) 2018-11-09
JP2019510025A (ja) 2019-04-11
US10662162B2 (en) 2020-05-26
EP3433258A1 (en) 2019-01-30
RU2018137032A3 (pt) 2020-05-22
RU2018137032A (ru) 2020-04-27
CA3018180C (en) 2024-02-20
AU2017237929A1 (en) 2018-09-13

Similar Documents

Publication Publication Date Title
MX2018011136A (es) Pirimidinas y variantes de estas, y usos de estas.
MX2018011622A (es) Pirimidinas y sus variantes, y usos de las mismas.
CL2021000343A1 (es) Inhibidores peptídicos del receptor de interleucina 23 (divisional de la solicitud n° 201800128)
CY1119766T1 (el) Νεοι ρυθμιστες κινασης βενζοπυρανιου
CY1122265T1 (el) Αντισωματα εναντι ταυ και χρησεις αυτων
CY1121359T1 (el) Ενωσεις ετεροαρυλιου για αναστολη κινασης
CY1124918T1 (el) Ρυθμιστες ccr2
CL2021000163A1 (es) Anticuerpos anti-htra1 y metodos de usos de los mismos. (divisional de solicitud 201801139)
FR24C1010I1 (fr) Modulateurs des récepteurs p2x3 et p2x2/3 de diaminopyrimidine destinés à être utilisés dans le traitement de la toux
CL2018003556A1 (es) Anticuerpos anti-ige.
BR112018074978A2 (pt) anticorpos para alfa-sinucleína e usos dos mesmos
DK3506909T3 (da) 4'-phosphatanaloger og oligonukleotider omfattende samme
BR112016025048A2 (pt) compostos e composições como agonistas do receptor tipo toll7
BR112020003865A8 (pt) Composições farmacêuticas compreendendo sepiapterina e seus usos
BR112018000542A2 (pt) composições de irna de transtirretina (ttr) e métodos de uso das mesmas para o tratamento ou prevenção de doenças associadas à ttr
SV2018005775A (es) Forma polimorfa de n-{6-(2-hidroxipropan-2-il)-2-[2-(metilsulfonil)etil]-2h-indazol-5-il}-6-(trifluorometil)piridin-2- carboxamida
BR112018010564A2 (pt) composições farmacêuticas compreendendo levodopa amida e usos das mesmas
CL2016002084A1 (es) Compuestos derivados de ciclopentano 1,2 substituidos como antagonistas del receptor de orexina.
CL2015000717A1 (es) Compuestos derivados de piridinonas biciclicas y sus sales; composicion farmaceutica que los comprende; y su uso para el tratamiento de la neurodegeneracion y trastornos psiquiatricos, que incluyen enfermedad de alzheimer o enfermedad de niemann-pick tipo c.
ES2980935T3 (es) Antagonista del receptor p2x3 y/o p2x2/3, composición farmacéutica que lo comprende y su uso
CL2019000050A1 (es) Procesos para la preparacion de oxipicolinamidas 4 - alkoxi - (acil o aquil).
CY1123359T1 (el) Τροποποιητες ετεροαρωματικου υπολοχεα nmda και χρησεις αυτων
BR112017022208A2 (pt) sistema espinhal poliaxial expansível
CY1124540T1 (el) Συνθεσεις και μεθοδοι που σχετιζονται με αγωνιστες 5-ht1f πυριδινοϋλοπιπεριδινης
CY1123013T1 (el) Συνδυασμος των καθαρων ανταγωνιστων του υποδοχεα 5-ητ6 με τους αναστολεις της ακετυλοχολινεστερασης

Legal Events

Date Code Title Description
B350 Update of information on the portal [chapter 15.35 patent gazette]
B15K Others concerning applications: alteration of classification

Free format text: A CLASSIFICACAO ANTERIOR ERA: C07D 487/04

Ipc: C07D 487/04 (2006.01), C07D 239/48 (2006.01), C07D

B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]
B25G Requested change of headquarter approved

Owner name: AFFERENT PHARMACEUTICALS INC. (US)

B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 20/03/2017, OBSERVADAS AS CONDICOES LEGAIS